Online citations, reference lists, and bibliographies.
← Back to Search

Studies Of The HER-2/neu Proto-oncogene In Human Breast And Ovarian Cancer.

D. Slamon, W. Godolphin, L. Jones, J. Holt, S. Wong, D. Keith, W. Levin, S. Stuart, J. Udove, A. Ullrich
Published 1989 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Carcinoma of the breast and ovary account for one-third of all cancers occurring in women and together are responsible for approximately one-quarter of cancer-related deaths in females. The HER-2/neu proto-oncogene is amplified in 25 to 30 percent of human primary breast cancers and this alteration is associated with disease behavior. In this report, several similarities were found in the biology of HER-2/neu in breast and ovarian cancer, including a similar incidence of amplification, a direct correlation between amplification and over-expression, evidence of tumors in which overexpression occurs without amplification, and the association between gene alteration and clinical outcome. A comprehensive study of the gene and its products (RNA and protein) was simultaneously performed on a large number of both tumor types. This analysis identified several potential shortcomings of the various methods used to evaluate HER-2/neu in these diseases (Southern, Northern, and Western blots, and immunohistochemistry) and provided information regarding considerations that should be addressed when studying a gene or gene product in human tissue. The data presented further support the concept that the HER-2/neu gene may be involved in the pathogenesis of some human cancers.
This paper references
Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease.
D. Zhou (1989)
10.1146/ANNUREV.GE.18.120184.003005
The molecular genetics of cellular oncogenes.
H. Varmus (1984)
10.1016/S0140-6736(87)92736-X
OVEREXPRESSION OF THE c-erbB-2 ONCOPROTEIN IN HUMAN BREAST CARCINOMAS: IMMUNOHISTOLOGICAL ASSESSMENT CORRELATES WITH GENE AMPLIFICATION
DeonJ. Venter (1987)
10.1038/312513A0
The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen
Alan L. Schechter (1984)
10.1126/SCIENCE.2999974
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.
L. Coussens (1985)
10.1177/34.8.2426335
The influence of protease digestion and duration of fixation on the immunostaining of keratins. A comparison of formalin and ethanol fixation.
H. Battifora (1986)
10.1210/ENDO-122-3-1165
Localization of progesterone receptor with monoclonal antibodies to the human progestin receptor.
M. Press (1988)
10.1073/PNAS.84.20.7159
Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.
R. Hudziak (1987)
10.1126/SCIENCE.3289120
Amplification of c-erbB-2 and aggressive human breast tumors?
D. Slamon (1988)
10.1038/290261A0
Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts
C. Shih (1981)
10.1056/NEJM198710083171509
Proto-oncogenes and human cancers.
D. Slamon (1987)
Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.
M. Berger (1988)
Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer.
D. Zhou (1987)
10.1126/SCIENCE.2885917
erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.
P. D. Di Fiore (1987)
10.1016/0092-8674(88)90184-5
Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene
W. Muller (1988)
10.1146/ANNUREV.BI.52.070183.001505
Cellular oncogenes and retroviruses.
J. Bishop (1983)
10.1016/0092-8674(86)90779-8
Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185
C. Bargmann (1986)
Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.
J. Varley (1987)
Immunocytochemical identification of estrogen receptor in ovarian carcinomas. Localization with monoclonal estrophilin antibodies compared with biochemical assays.
M. Press (1985)
10.1038/bjc.1988.239
c-erbB-2 expression in benign and malignant breast disease.
B. Gusterson (1988)
10.1126/SCIENCE.6538699
Expression of cellular oncogenes in human malignancies.
D. Slamon (1984)
10.1093/AJCP/90.3.233
The evaluation of estrogen receptor in primary breast carcinoma by computer-assisted image analysis.
S. Bacus (1988)
10.1056/NEJM198811103191902
Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.
M. J. van de Vijver (1988)
Estrogen and Progestin Binding in Cytosols of Ovarian Adenocarcinomas
J. Holt (1979)
Amplification and over-expression of the neu oncogene in human breast carcinomas.
M. J. van de Vijver (1988)
10.1038/bjc.1988.238
An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma.
D. Barnes (1988)
An immunocytochemical method for demonstrating estrogen receptor in human uterus using monoclonal antibodies to human estrophilin.
M. Press (1984)
Expression of p21 ras oncoproteins in human cancers.
T. Tanaka (1986)
10.1126/SCIENCE.3008339
Identification and characterization of the protein encoded by the human N-myc oncogene.
D. Slamon (1986)
10.1126/SCIENCE.3014652
Studies of the human c-myb gene and its product in human acute leukemias.
D. Slamon (1986)
10.1126/SCIENCE.240.4860.1796
In Reply: Amplification c-erbB-2 and Aggressive Human Breast Tumors?
D. Slamon (1988)
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.
C. Wright (1989)
10.1126/SCIENCE.3798106
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)



This paper is referenced by
10.1155/2015/427235
Physicochemical and Biological Characterization of a Biosimilar Trastuzumab
C. López-Morales (2015)
ERRF sensitizes ERBB 2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL 1 and ERBB 2 expression
Leilei Qi ()
10.5772/26943
Prognostic Factors in Renal Cell Carcinoma: An Evaluation of T-Stage, Histopathological Grade, p53, Ki-67, COX-2, and Her-2 Expressions
M. Kankuri-Tammilehto (2012)
10.5772/INTECHOPEN.72695
Genomic Copy Number Alterations in Serous Ovarian Cancer
Joe R. Delaney (2018)
10.1007/978-3-030-50287-4
Cancer Immunology: Bench to Bedside Immunotherapy of Cancers
N. Rezaei (2021)
10.7150/thno.17927
Incorporating gold nanoclusters and target-directed liposomes as a synergistic amplified colorimetric sensor for HER2-positive breast cancer cell detection
Y. Tao (2017)
10.1200/JCO.2009.24.1661
Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.
L. Gianni (2010)
10.1038/s41598-020-59630-y
ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer patients undergoing therapy with trastuzumab
Valentina Agnolon (2020)
10.1016/j.chroma.2020.460974
Preparation and application of immunoaffinity in-tube solid phase microextraction column with oriented antibody-immobilized porous layer open tubular capillary for high sensitive quantification of serum extracellular domain of human epidermal growth factor receptor 2 levels.
Jianhui Pan (2020)
10.2147/BCTT.S6956
Progress in the development of a therapeutic vaccine for breast cancer.
A. Coveler (2010)
10.21236/ada535016
Targeting IKK in Basal-Like Breast Tumors as a Therapeutic Approach
A. Baldwin (2010)
10.1007/b112626
Microscopy, Immunohistochemistry, and Antigen Retrieval Methods
M. A. Hayat (2002)
10.1159/000055398
Testing for HER2 Status
W. Hanna (2001)
10.2741/1138
SRC in human carcinogenesis.
Salvatore V Russello (2004)
10.1016/S0090-8258(03)00460-8
Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy.
S. Bellone (2003)
10.1158/0008-5472.CAN-03-2914
Caspase-8-dependent HER-2 cleavage in response to tumor necrosis factor alpha stimulation is counteracted by nuclear factor kappaB through c-FLIP-L expression.
V. Benoît (2004)
10.5650/OLEOSCIENCE.4.367
ナノテクノロジーに関与する微粒子製剤の最近の話題 (2) 医薬品
文由 石井 (2004)
10.4321/S0210-48062005000100009
Estudio de la expresión de cerbB-2 en el adenocarcinoma de próstata
P. Fraile (2005)
10.1016/J.CTRV.2005.04.008
Central nervous system metastases in breast cancer patients administered trastuzumab.
R. Duchnowska (2005)
10.1016/J.MRFMMM.2004.10.013
Transgenic mouse models for the prevention of breast cancer.
Q. Shen (2005)
10.3748/WJG.V11.I31.4771
Bio-feedback treatment of fecal incontinence: where are we, and where are we going?
G. Chiarioni (2005)
10.1093/JNCI/DJI249
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
G. Arpino (2005)
10.1073/PNAS.0508677102
Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents.
G. Zheng (2005)
10.1007/978-1-59745-035-5_25
Role of TGF-β in Tumor Progression and Metastasis
J. Pinkas (2006)
10.1155/2004/532413
No Amplifications of Hypoxia-Inducible Factor-1α Gene in Invasive Breast Cancer: A Tissue Microarray Study
M. M. Vleugel (2004)
10.1016/J.BREAST.2005.08.027
Biological variables and prognosis of DCIS.
M. Vijver (2005)
10.1016/J.CANLET.2005.01.041
Herceptin: mechanisms of action and resistance.
R. Nahta (2006)
Molecular analysis of early onset Indonesian breast cancer
D. Purnomosari (2006)
10.1038/onc.2009.497
Multiple microRNAs rescue from Ras-induced senescence by inhibiting p21Waf1/Cip1
V. Borgdorff (2010)
10.1016/j.lfs.2010.02.018
Gamma- and delta-tocotrienols exert a more potent anticancer effect than alpha-tocopheryl succinate on breast cancer cell lines irrespective of HER-2/neu expression.
E. Pierpaoli (2010)
The anti-tumourigenic action of the progesterone receptor antagonist Lonaprisan (ZK230211) in breast cancer
L. Busia (2011)
COMPARISON OF CARDIOTOXIC EFFECTS OF DIFFERENT ERB-B2 INHIBITORS AND THEIR
Dottorato Di Ricerca (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar